MXPA03010632A - Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos. - Google Patents

Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.

Info

Publication number
MXPA03010632A
MXPA03010632A MXPA03010632A MXPA03010632A MXPA03010632A MX PA03010632 A MXPA03010632 A MX PA03010632A MX PA03010632 A MXPA03010632 A MX PA03010632A MX PA03010632 A MXPA03010632 A MX PA03010632A MX PA03010632 A MXPA03010632 A MX PA03010632A
Authority
MX
Mexico
Prior art keywords
inhibitors
kappa
dry eye
eye disorders
treat dry
Prior art date
Application number
MXPA03010632A
Other languages
English (en)
Inventor
M Yanni John
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MXPA03010632A publication Critical patent/MXPA03010632A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los inhibidores de NF-KB son utiles para tratar trastornos de resequedad de ojos y otros trastornos que requieren la humectacion del ojo.
MXPA03010632A 2001-05-21 2002-05-17 Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos. MXPA03010632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29249501P 2001-05-21 2001-05-21
PCT/US2002/015859 WO2002095704A1 (en) 2001-05-21 2002-05-17 Use of nf-kappa-b inhibitors to treat dry eye disorders

Publications (1)

Publication Number Publication Date
MXPA03010632A true MXPA03010632A (es) 2004-03-09

Family

ID=23124921

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010632A MXPA03010632A (es) 2001-05-21 2002-05-17 Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.

Country Status (17)

Country Link
US (1) US6696453B2 (es)
EP (1) EP1393277B1 (es)
JP (1) JP2004527578A (es)
CN (1) CN1509462A (es)
AT (1) ATE333273T1 (es)
AU (1) AU2002309963B2 (es)
BR (1) BR0209965A (es)
CA (1) CA2447883A1 (es)
CY (1) CY1105220T1 (es)
DE (1) DE60213230T2 (es)
DK (1) DK1393277T3 (es)
ES (1) ES2263785T3 (es)
MX (1) MXPA03010632A (es)
PL (1) PL367286A1 (es)
PT (1) PT1393277E (es)
WO (1) WO2002095704A1 (es)
ZA (1) ZA200308769B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374700A1 (en) * 2002-09-20 2005-10-31 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4996209A (en) 1988-06-20 1991-02-26 Alcon Laboratories, Inc. Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofen
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
AU674681B2 (en) 1992-04-21 1997-01-09 Schepens Eye Research Institute, Inc., The Ocular androgen therapy in Sjogren's syndrome
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
FR2718441B1 (fr) 1994-04-07 1996-06-28 Bioxytech Nouveaux composés de structure benzisoséléna-zoline et -zine, leur procédé de préparation et leurs applications thérapeutiques.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU715430B2 (en) 1995-08-14 2000-02-03 Optigenex, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
KR100598723B1 (ko) 1998-07-14 2006-07-11 알콘 매뉴팩츄어링, 리미티드 비알레르기성 안염증 질환 치료 및 안혈관신생 예방용약제를 제조하기 위한11-(3-디메틸아미노프로필리덴)-6,11-디하이드로디벤즈[β,ε]옥세핀-2-아세트산의 용도
WO2000043000A1 (fr) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
EP1173413B1 (en) 1999-04-27 2004-06-30 Novartis AG Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
AU2002309963B2 (en) 2007-03-01
CY1105220T1 (el) 2010-03-03
ES2263785T3 (es) 2006-12-16
WO2002095704A8 (en) 2003-09-18
CA2447883A1 (en) 2002-11-28
JP2004527578A (ja) 2004-09-09
PL367286A1 (en) 2005-02-21
PT1393277E (pt) 2006-09-29
WO2002095704A1 (en) 2002-11-28
DE60213230T2 (de) 2006-11-23
CN1509462A (zh) 2004-06-30
US6696453B2 (en) 2004-02-24
EP1393277B1 (en) 2006-07-19
DK1393277T3 (da) 2006-10-30
WO2002095704A9 (en) 2003-02-27
DE60213230D1 (de) 2006-08-31
EP1393277A1 (en) 2004-03-03
ZA200308769B (en) 2005-01-26
ATE333273T1 (de) 2006-08-15
US20030008854A1 (en) 2003-01-09
BR0209965A (pt) 2004-04-06

Similar Documents

Publication Publication Date Title
AU2002305756A8 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
IL143870A0 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
MXPA04002593A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
HK1051499A1 (en) Method for treating ocular pain
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
EP1546377A4 (en) METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISORDERS USING MOLECULES 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 OR 13424
MXPA03010632A (es) Uso de inhibidores de nf-kb para tratar trastornos de resequedad de ojos.
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
EP1372648A4 (en) KIEASE TIE2 RECEPTOR INHIBITORS FOR THE TREATMENT OF ANGIOGENIC DISEASES
MXPA03000313A (es) Uso de fosfato de estramustina en el tratamiento de metastasis osea.
HK1059391A1 (en) Use of quetiapine for the treatment of cocaine dependence
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
EP1517912A4 (en) METHODS AND COMPOSITIONS FOR TREATING PAIN AND PAIN DISEASES USING GENES 577, 20739 OR 57145

Legal Events

Date Code Title Description
FG Grant or registration